Personalized medicine - the promised land: Are we there yet?

Clinical Genetics

Volumn 79, Issue 5, 2011, Pages 403-412

  Li, C ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Delivery of genetics care, personalized medicine; Omics

Indexed keywords

PROTEOME; TRANSCRIPTOME;

CLINICAL GENETICS; COST; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; GOVERNMENT; GOVERNMENT REGULATION; HAPLOTYPE; HEALTH CARE UTILIZATION; HUMAN; HUMAN GENOME; HUMAN GENOME PROJECT; MEDICAL ETHICS; MEDICOLEGAL ASPECT; METABOLOME; METAGENOME; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDITY;

GENETIC TESTING; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 79953746638     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2010.01609.x     Document Type: Review

References (32)

1. Edwards AO, Ritter R. 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005: 308: 421-424.
2. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 2006: 38: 1173-1177.
3. Swaroop A, Chew EY, Bowes Rickman C, Abecasis GR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet 2009: 10: 19-43.
4. Ku CS, Loy EY, Pawitan Y, Chia KS. The pursuit of genome-wide association studies: where are we now? J Hum Genet 2010: 55: 195-206.
5. Ku CS, Loy EY, Salim A, Pawitan Y, Chia KS. The discovery of human genetic variations & their use as disease makers: past, present & future. J Hum Genet 2010: 55: 403-415.
6. Waalen J, Beutler E. Genetic screening for low-penetrance variants in protein-coding genes. Annu Rev Genomics Hum Genet 2009: 10: 431-450.
7. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001: 285: 2216-2222.
8. Hemochromatosis. Accessed on December 20, 2010.
9. Guttmacher AE, McGuire AL, Ponder B, Stefansson K. Personalized genomic information: preparing for the future of genetic medicine. Nat Rev Genet 2010: 11: 161-165.
10. Scheuner MT, Whitworth WC, McGruder H, Yoon PW, Khoury MJ. Expanding the definition of a positive family history for early-onset coronary heart disease. Genet Med 2006: 8: 491-501.
11. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009: 461: 399-402.
12. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Rev Genet 2009: 41: 1100-1104.
13. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Rev Genet 2009: 41: 1105-1109.
14. Iadonato SP, Katze MG. Hepatitis C gets personal. Nature 2009: 461: 357-358.
15. Janssens CJW, van Duijn CM. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008: 17: R166-R173.
16. Green ED. The genomic landscape: circa 2010 in Current Topics in Genome Analysis. Accessed on December 20, 2010.
17. Moline J, Eng C. Multiple endocrime neoplasia type 2. In GeneReview. Accessed on December 20, 2010.
18. Lohmann D, Gallie B. Retinoblastoma. In GeneReview. Accessed on December 20, 2010.
19. Glazko G, Veeramachaneni V, Nei M, Makałowski W. Eighty percent of proteins are different between humans and chimpanzees. Gene 2005: 346: 215-219.
20. Knowles DG, McLysaght A. Recent de novo origin of human protein-coding genes. Genome Res 2009: 19: 1752-1759.
21. Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2009: 457: 480-484.
22. Capasso M, Diskin SJ. Genetic and genomics of neuroblastoma. Cancer Treat Res 2010: 155: 65-84.
23. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: singling in development and disease. Biochem J 2009: 420: 345-361.
24. Schmidt A, Gehlenborg N, Bodenmiller B et al. An integrated, directed mass spectrometric approach for in-depth characterization of complex peptide mixtures. Mol Cell Proteomics 2008: 7: 2138-2150.
25. Costa R, Carneiro A, Rocha A et al. Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study. J Cell Biochem 2009: 108: 1410-1417.
26. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009: 158: 1-9.
27. Peeters M, Siena S, Van Cutsem E et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009: 115: 1544-1554.
28. Visintin I, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008: 14: 1065-1072.
29. Zhu H, Hu S, Jona G et al. Severe acute respiratory syndrome diagnostics using a coronavirus protein microarray. Proc Natl Acad Sci U S A 2006: 103: 4011-4016.
30. Kaye J. The regulation of direct-to-consumer genetic tests. Hum Mol Genet 2008: 17 (R2): R180-183.
31. Gurwitz D. Bregman-Eschet Y. Personal genomics services: whose genomes? Eur J Hum Genet 2009: 17: 883-889.
32. Thompson IM, Lucia MS, Tangen CM. Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9. Int J Epidemiol 2007: 36: 287-289.